Chemotherapy and bone marrow transplant are the standard-of-care for AML. Now the basic science from Jordan’s lab and the results from clinical trials in Pollyea’s and Smith’s patients are leading to a new paradigm for the treatment of AML.
Cancer Center announces two newly endowed chairs: Daniel Pollyea, MD, recipient of the Robert H. Allen Endowed Chair in Hematology Research, and Eric Pietras, PhD, recipient of the Ceo Meador/George Ryland Scott Endowed Chair in Hematology Research.
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML).
Cancer gets energy in the form of glucose. But how does it get this glucose? A recent study shows that leukemia undercuts the ability of normal cells to consume glucose, leaving more glucose available to feed its own growth.